LON:SKP - SkyePharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseGBX 444
Today's RangeN/A
52-Week RangeGBX 249.25 - GBX 486.25
VolumeN/A
Average Volume177,955 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Skyepharma Ltd, formerly Skyepharma PLC, is a drug delivery company engaged in the development of oral and inhalation products. The Company operates as an independent developer of complex pharmaceutical products for global markets. Its principal activities are the generation and development of product and drug delivery technology concepts, involving the application of its inhalation and oral technologies. It operates through the segment of development and supply of pharmaceutical products. It is also involved in the supply of products to its marketing partners, as in the case for flutiform and over seven oral products manufactured in its Lyon Facility. It operates primarily for respiratory applications. Its inhalation products include Relvar Ellipta/Breo Ellipta, Anoro Ellipta and Incruse Ellipta. Its oral products include RAYOS/LODOTRA, Requip Once-a-day, Xatral/Uroxatral, Madopar DR/Prolopa, Sular, ZYFLO CR, Paxil CR, Diclofenacratiopharm Uno, Triglide and Coruno.

Receive SKP News and Ratings via Email

Sign-up to receive the latest news and ratings for SKP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
WebN/A
Phone+44-20-78810524

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
OptionableNot Optionable

SkyePharma (LON:SKP) Frequently Asked Questions

What is SkyePharma's stock symbol?

SkyePharma trades on the London Stock Exchange (LON) under the ticker symbol "SKP."

Has SkyePharma been receiving favorable news coverage?

Media stories about SKP stock have been trending somewhat negative on Saturday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SkyePharma earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.

How do I buy shares of SkyePharma?

Shares of SKP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How can I contact SkyePharma?

SkyePharma's mailing address is 46-48 Grosvenor Gardens, LONDON, SW1W 0EB, United Kingdom. The company can be reached via phone at +44-20-78810524.


MarketBeat Community Rating for SkyePharma (LON SKP)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about SkyePharma and other stocks. Vote "Outperform" if you believe SKP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SKP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel